Clinical trial
Open-Label, Randomized, Multicenter Clinical Trial to Evaluate the Cardioprotective Effect, Determine Optimal Dosages and Duration of Inhalation, and Confirm the Clinical Safety of the Medicinal Product Aroxxen® in Patients Who Have Undergone Elective Percutaneous Coronary Intervention With Stent Implantation (Phase II)
NCT07397351 is registered in ClinicalTrials.gov with Research Institute of Geroprotective Technologies as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open-Label, Randomized, Multicenter Clinical Trial to Evaluate the Cardioprotective Effect, Determine Optimal Dosages and Duration of Inhalation, and Confirm the Clinical Safety of the Medicinal Product Aroxxen® in Patients Who Have Undergone Elective Percutaneous Coronary Intervention With Stent Implantation (Phase II)
- Lead sponsor
- Research Institute of Geroprotective Technologies
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- March 5, 2026
- Completion date
- December 31, 2026
- Enrollment
- 180 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.